论文部分内容阅读
人类免疫缺陷病毒1型(HIV-1)在全球的广泛流行迫切需要研制一种安全、有效的HIV疫苗。多年研究表明能否诱生机体产生有效的HIV-1特异性T细胞应答(尤其CTL)是HIV疫苗成功的关键。鉴于HIV-1重组痘病毒疫苗和DNA疫苗能诱生一定强度的HIV-1特异性CTL反应,但各自保护作用有限的缺陷,本文作者提出一种新的免疫策略:先用HIV-1的DNA疫苗进行初次免疫,再用相应的重组禽痘病毒疫苗(rFPV)加强免疫。研究发现该策略能有效提高两疫苗诱发特异性T细胞免疫的能力及其免疫保护作用。
The worldwide epidemic of human immunodeficiency virus type 1 (HIV-1) urgently requires the development of a safe and effective HIV vaccine. Years of research have shown that the induction of an effective HIV-1-specific T cell response in the body, especially CTL, is key to the success of the HIV vaccine. In view of HIV-1 recombinant poxvirus vaccine and DNA vaccine can induce a certain intensity of HIV-1-specific CTL response, but their respective limitations of limited protection, the authors propose a new immunization strategy: HIV-1 DNA The vaccine was first immunized and then boosted with the corresponding recombinant fowlpox virus vaccine (rFPV). The study found that the strategy can effectively improve the ability of two vaccines to induce specific T cell immunity and its immune protection.